Early-stage decay and gum inflammation can often be treated effectively
This activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and reduces appetite through central nervous system pathways
Lead author Dr Simon Cork, Physiology lead at Anglia Ruskin Universitys School of Medicine, said: This new review provides one of the most comprehensive analyses so far of how GLP1 drugs interact with the underlying mechanisms of Alzheimers
A rigorous 2026 UK review covering the November 2025 FDA approval of Caplyta (lumateperone) for major depressive Read the full review Psychiatry & Cognitive Health 19 May 2026 Dihexa for Schizophrenia: KarXT/Cobenfy, Iclepertin CONNEX Failure, BDNF, C4 Pruning & the 2026 UK Review Can Dihexa help schizophrenia, cognitive impairment associated with schizophrenia (CIAS) or negative symptoms
TABLE 1 Baseline demographic factors and comorbidities of study population according to GLP1-RA use
Genetic predisposition does not predict exact medication response but may support a more informed treatment conversation
